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ABSTRACT 
Background 
HIV is a worldwide pandemic with an estimated 2.5 million children under the age of 15 living with 
HIV in the world in 2009. Children account for approximately 14% of all HIV-related deaths around 
the world. Several studies have shown that the use of antiretroviral drugs greatly improve the lives of 
HIV-1 infected individuals, however, most of these studies report on outcomes of ART programmes in 
developed world and for adult patients. Very few settings have published outcomes of paediatric ART 
programmes. 
 
Objectives 
This research was aimed at describing the long term (at least one year) treatment outcome of HIV-1 
infected children in the HIV/AIDS Prevention Group (HAPG) program in Bela-Bela in the Limpopo 
province of South Africa.  
 
Study design and methods 
A quantitative approach involving a retrospective cohort design was used for the study. The study 
included all children under the age of 15 that were enrolled in the HATG treatment programme in Bela-
Bela between February 2004 and December 2009. Immunological, virological, clinical outcomes and 
loss to follow-up were determined for this cohort. Mortality and survival was also determined. 
 
Results 
The median age of children in this study was 5 years (IQR: 2-7) with 14% (10/71) of them being less 
than 18 months. Median CD4 count at commencement of ART, viral load and weight were 358 
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cells/mm3 (IQR 203.5-, 125673 RNA copies/µL (IQR 58094-328424.5) and 14.5Kg (IQR: 11.0-18.35) 
respectively.  CD4 counts and weight showed increase within the study period, and there was also a 
decline in viral load. Loss to follow-up was 7.04% while mortality was 19% with 21.43% of mortality 
cases being children who were ≤18months. Mortality occurred within the first year of ART initiation 
and occurred in cases that had advanced disease. 
 
Conclusion 
This study shows that the ART program in Bela-Bela has a positive outcome on HIV positive children. 
The high mortality rate was due to children starting ART at an advanced disease stage. Despite the good 
outcome, it is recommended that a system be put into place that will aid in identifying children at an 
early stage of the disease and treatment initiated promptly. 
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CHAPTER 1:  INTRODUCTION 
1.1 Introduction 
It was estimated that 2.5 million children who are under the age of 15 years were living with the 
human immunodeficiency virus (HIV) around the world in 2009 (UNICEF, 2010). Approximately 
430,000 new infections were reported in this same year and about ninety percent of the estimated 
number of children living with HIV is found in Sub-Sahara Africa (Barth et al, 2010). New infections 
in children are believed to be due to mother to child transmission (MTCT) either in utero, during 
delivery or through breastfeeding. In total, children account for 8% of all HIV infections and 14% of 
all HIV-related deaths (UNICEF, 2010). 
 
Several challenges are faced by resource-limited countries in the delivery of antiretroviral treatment 
(ART) to children under the age of 15 years. These challenges range from lack of early diagnosis and 
monitoring techniques, lack of health care infrastructure, limited availability of paediatric ARV 
formulations, lack of human resources in pediatric HIV care delivery, and limited funds to sustain 
treatment programmes (Paintsil, 2007). Despite these challenges, some countries with limited 
resources for pediatric ART delivery still report good treatment outcomes that are comparable to those 
in high-income countries (Sutcliffe et al, 2008). 
  
South Africa has the largest paediatric antiretroviral treatment (ART) programme in the world, with an 
estimated 32 000 children under 15 years of age receiving treatment at the end of 2007 (WHO, 
UNICEF, UNAIDS, 2008). 1n South Africa, the proportion of newly infected children starting ART 
increased from 2.1% between mid-2002 and mid-2003, to 36.9% between mid-2007 and mid-2008 
(Department of Health [DoH], 2009). Variation in access to ART for children exists between 
provinces with the Western Cape having coverage of 96.9% in the 2007/2008 period while only 22.1% 
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of children in the Free State were able to access ART (DoH, 2009). Variations can also be seen within 
provinces with children in urban areas having more access than those in rural areas.  
 
Generally, contextual factors may play a role in the success of interventions. These factors may 
include political will and leadership, the status of women, stigmatization of high risk groups and the 
presence of armed conflicts and social unrest (Campbell, 2010). In the case of children, outcome of 
treatment may be linked to adherence which is influenced by factors such as dosing, medicine 
formulation (children being reluctant to take the drugs in powder or syrup form due to their unpleasant 
taste), dietary restrictions and toxic side effects. The socio-economic status of children may also 
influence adherence (Fennel, 2010). In rural Limpopo, social factors that influence treatment outcome 
include stigma, the practice of faith healing and certain traditional practices (Campbell, 2010). Even 
though access to most HIV treatment programmes are free, the quality of care and the distance to 
treatment centres contribute to the utilization of these programmes and therefore the outcome.  
 
1.2 Problem statement 
Intervention measures to fight against HIV/AIDS include measures that target behaviours, social and 
cultural drivers of the disease and also biological drivers. Though prevention efforts to reduce the 
transmission and spread of the disease will help curb the pandemic, there is the need to treat those who 
are already infected which doubles as a preventive and a control measure. Treatment programs around 
the world have shown positive effects on patients but these programs have not been replicated in some 
resource limited settings. It is essential that policy makers and program planners have full description 
of intervention measures and estimates of the effect of interventions on a group of people or the public 
to be able to make appropriate decisions that will affect research and funding for particular programs. 
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In South Africa, treatment with ARVs is of great importance due to the high burden of disease in the 
country. Many treatment programs have been evaluated and recommendations made to policy makers, 
however, most of these programs are focused on adult and in better resourced clinics particularly in 
urban areas (Davies et al, 2009; Ingle et al, 2010). In some rural programs, virologic data are usually 
not available and in certain cases, virologic, immunologic and clinical data where available, are 
limited to short term follow-up (approximately 1 year follow-up) with very few studies reporting on 
outcome after 3 years of follow-up (Barth et al, 2011). Since the start of the HIV treatment program by 
the HIV/AIDS Prevention Group (HAPG) in Bela-Bela in the Limpopo province, there has been no 
published study that describes the outcome (short- or long-term) of this program. 
Consultation for this project started mid January 2011, initially between Dr. Bessong Pascal (Head of 
Microbiology Department and Head of the AIDS research Laboratory at the University of Venda) who 
is one of the board members of the HAPG and Ms Cecile Manhaeve who is chair of the board and also 
actively participate in the day-to-day running of the clinic in Bela-Bela. Their discussion centered on the 
lack of information on the outcome of the program since its initiation. By the end of February 2011, in 
consultation with a statistician, it was agreed that this study be conducted. Formal discussions with Dr. 
Bessong, Cecile, Prof Amey (the statistician) and myself concerning the children (<15 years) aspect of 
the study has taken place and there is constant communication amongst us on the different aspects of the 
study (including the adult outcome and the overall outcome of the program).   
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 The HIV/AIDS pandemic 
The Human Immunodeficiency Virus type 1 (HIV-1) has been identified as the etiologic agent causing 
the acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans that cause the 
immune system to fail leading to a decrease in the ability of the system to fight disease therefore 
allowing opportunistic infections and certain cancers to thrive. The HI virus can be transmitted in 
many different ways. The majority of infections are acquired through unprotected sexual intercourse 
(vaginal or anal) with an infected individual. Sharing of contaminated injection materials and sharps 
constitute an important transmission route. Transfusion of contaminated blood and blood products has 
also been documented. Transmission from mother to child in utero, during delivery or through 
breastfeeding is the predominant method of infection in children (WHO 2012 fact sheet). 
 
Since its discovery approximately three decades ago, AIDS has been identified as the most deadly 
infectious disease in the world with WHO and the UNAIDS estimating over 25 million deaths due to 
HIV/AIDS (UNAIDS, 2010). In 2010 alone, approximately 2.8 million people died of HIV/AIDS. An 
estimated 34 million people were living with HIV/AIDS world wide by the end of 2010, with an 
estimated 22.5 million from Sub-Sahara Africa which remains the region most affected by the 
pandemic. Sub-Sahara Africa alone accounts for approximately 67% of infections worldwide and 
experienced a 1.2 million deaths from the disease in 2010 alone (UNAIDS, 2010).  
The epidemic in South Africa remains one of the highest in the world with an estimated 5.6 million 
people living with HIV at the end of 2009 and over 48,000 new infections in 2010. Deaths due to 
AIDS in South Africa in 2009 was estimated at 310,000. A variation exists in the prevalence of HIV in 
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South Africa based on age, gender, race, socio-economic status and geographic location. HIV 
prevalence ranges from as low as 18.4% in the Northern Cape Province to as high as 39.5% in 
KwaZulu-Natal province. The prevalence in Limpopo in 2010 among antenatal clinic attendees was 
21.9% increasing from14.5% in 2001 and 20.7% in 2007 (UNAIDS, 2010; DOH, 2011). Prevalence in 
the overall Limpopo population for 2008 was estimated at 8.8%. 
2.1 HIV Prevention and Treatment 
With an almost thorough knowledge of how the virus is transmitted, and advances in the knowledge of 
its life cycle, molecular structure and its interaction with its host, many different methods have been 
designed to fight HIV and AIDS. Prevention in the context of HIV/AIDS involves preventing 
transmission and spread of the virus, preventing and controlling infection by opportunistic 
microorganisms and slowing the transition from virus infection to AIDS development. One of the most 
celebrated measures that have been used to fight major infectious diseases in the past has been the use 
of vaccines. Development of a safe and efficacious vaccine against HIV remains one of the top global 
health priorities and the best solution for the long term prevention and control of HIV/AIDS. There 
have been several attempts at vaccine development and trials (Rerks-Ngarm et al, 2009; Buchbinder et 
al, 2008) but to date, there is no approved vaccine against HIV/ AIDS. While research in the field of 
vaccine development continues, other measures have been and are still being put into place for the 
prevention and control of the pandemic. 
 
Measures that target risk behaviours such as the number of sex partners, unprotected sex and the 
sharing of contaminated needles have been shown to reduce HIV transmission (Cohen et al, 2004; 
Johnson et al, 2008). Voluntary counseling and testing (VCT) has also been shown to reduce some of 
these risk behaviours. Strategies that incorporate societal and cultural drivers of the disease such as 
stigmatization, discrimination, poverty, inequality, lack of education, migration and homelessness, can 
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also help prevent transmission and spread of HIV. Prevention and treatment of sexually transmitted 
diseases (STDs) constitute an important part of the fight against HIV. Studies have shown association 
between certain STDs and HIV (Mmbaga et al, 2011; Atashili et al, 2008). A study in South Africa 
that used a mathematical model to simulate the interaction between HIV and six STDs and two 
common vaginal infections (bacterial vaginosis and vagina candidiasis) revealed that these infections 
have significantly contributed to the spread of HIV in South Africa. The authors acknowledge that 
although the control of STDs has not shown great impact on South African HIV incidence because of 
late introduction and suboptimal coverage, control of STDs may go a long way to control HIV/AIDS 
(Johnson et al, 2012). The use of topical microbicides can also help prevent the spread of the disease 
(Klasse et al, 2006). 
 
2.3 Prevention of mother-to-child transmission (PMTCT) 
PMTCT can help reduce the number of children infected with HIV. Without any intervention, WHO 
estimates that the rate of transmission from mother to child could range from 15-45%.  
 Over the years, guidelines for the PMTCT have been updated however, all recommendations are 
based on evidence and are aimed at improving the health of both mother and child and reduction of 
transmission. WHO recommends that all HIV positive pregnant women who meet the criteria for 
treatment based on either clinical staging or CD4 counts should receive treatment. In this respect, 
women with CD4 counts less than 350/mm3 should receive treatment irrespective of the stage and 
women at stage 4 of the disease should receive treatment irrespective of CD4 counts (WHO, 2010 fact 
sheet; WHO, 2007)). WHO recommends a twice daily dose of AZT for the mother and her infant as 
prophylaxis and either AZT or Nevirapine (NVP) for a period of six weeks after birth for a non-
breastfeeding infant. For breastfeeding infants, a daily prophylactic treatment with NVP for up to one 
week after the mother stops breastfeeding. A second option involves a three-drug prohylaxis during 
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pregnancy and throughout the breastfeeding period including prophylaxis for the infant for six weeks 
after birth, irrespective of whether the infant is breastfeeding or not (WHO, 2010 fact sheet).  
 
In 2008, The South African Department of Health decided to institute a dual antiretroviral treatment as 
standard care for pregnant women whose CD4 counts were >200/mm3 and those with CD4 counts 
<200/mm3 were considered eligible for triple therapy. This guideline was changed in 2010 to provide 
triple antiretroviral treatment for all pregnant women with CD4 counts <350/mm3 (DOH, 2010). 
 
Treatment with antiretrovirals (ARVs) has been considered one of the most successful measures for 
HIV/AIDS prevention. Since the introduction of ART and the use of highly active antiretroviral 
therapy (HAART), there has been great improvement in the lives of people living with the disease 
with dramatic decrease in morbidity and mortality over the years. The UNAIDS reported a 17% 
increase in the number of people living with HIV/AIDS from 2001 to the end of 2010. In a negative 
light, this increase portrays an increase in prevalence, but in a positive light, it reflects the success of 
the use of ARVs in prolonging the lives of people infected with the virus. It was estimated that deaths 
due to AIDS decreased to 1.8million at the end of 2010 compared to 2.2 million in the mid 2000s 
(UNAIDS 2011) due to increase in access to antiretroviral drugs. Approximately 15 million people 
worldwide have access to ART. The benefits of ART have been echoed in many settings around the 
world (Dlodlo et al, 2011; Reniers et al, 2009; Jahn et al, 2008).  ARVs are known to reduce viral 
replication, thereby reducing viral load. Since viral load is a strong predictor of virus transmission 
between discordant partners, it is but evident that reduction in viral load through the use of ARVs will 
greatly reduce transmission of the virus between partners and therefore prevent the spread of the 
disease (Cohen et al 2011; DeGruttola et al, 2010). Although treatment brings forth hope in the fight 
against HIV/AIDS, ART to date is still expensive in some low and middle income settings and 
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adherence poses a problem due to the high pill burden.  It is therefore important that treatment be used 
in conjunction with other prevention strategies to be able to achieve maximum results. 
 
  2.4 HIV/AIDS in children 
WHO, UNAIDS and UNICEF in their 2011 report estimated that more than 3.4 million children under 
the age of 15 were living with HIV/AIDS at the end of 2010. An estimated 3.1 million of these 
children were from Sub-Saharan Africa accounting for 90% of the global infection in children. 
Approximately 390,000 new infections were registered for children in 2010. Like in adults, HIV in 
children can be transmitted through transfusion of infected blood or blood products, or use of 
unsterilized needles. Sharing of contaminated needles and syringes among homeless and street 
children for injecting drugs may also lead to transmission of the virus. Another mode of transmission 
may be through sexual intercourse. Although not a major mode of transmission in children, it may 
occur in communities where children become sexually active at a young age or when they are sexually 
abused or raped. 
 
Unlike in adults, the majority of children acquire HIV through mother-to-child transmission (MTCT) 
either during pregnancy, during labour and delivery or through breastfeeding (UNAIDS). It is 
estimated that without treatment, approximately 15-30% of children who are born to HIV positive 
mothers will be infected with the virus either in utero or during delivery while a further 2-20% will 
acquire the virus through breastfeeding (WHO 2006b). 
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 2.5 HIV prevention for children 
Since most cases of HIV in children occur through mother-to-child transmission, prevention of MTCT 
remains a major step towards reduction of the number of children infected with HIV/AIDS. PMTCT 
can be achieved through treatment with ARVs during pregnancy, childbirth and breastfeeding. Studies 
in resource-rich countries have shown that administration of Zidovudine during pregnancy and 
peripartum period lead to an initial reduction of perinatal transmission of HIV by 67%  and a 
subsequent reduction in perinatal transmission by 98%-99% with the use of highly active antiretroviral 
therapy (HAART) during pregnancy (Paintsil, 2010).  A study in Africa has also shown that mothers 
who took triple combination antiretroviral drugs during pregnancy had a reduced risk of transmitting 
the virus to their babies than women who took Zidovudine and single dose nevirapine (The Kesho 
Bora Study Group, 2011). To date, UNAIDS estimate that more than 350,000 new cases of HIV in 
children has been prevented through prophylactic treatment of HIV positive pregnant women 
(UNAIDS, 2011). These results, though very impressive, have not been achieved in most resource-
limited countries. UNAIDS estimated that only about half the number of pregnant women requiring 
drugs to prevent transmission to their babies were able to access them. Greater awareness and 
improvement in the availability of counseling, testing and treatment services still need to be provided 
in many resource-limited settings. 
A comprehensive approach to PMTCT was instituted by the UN which involves a four prong strategy. 
These strategies are:  
The primary prevention of HIV infection among women, especially those of childbearing age. For this 
approach, it is expected that prevention of infection in would-be parents and lactating mothers will 
eventually prevent infection of their children. Improvement in reproductive health services such as 
antenatal, postpartum and postnatal care including community support may help achieve this strategy. 
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The second prong is to prevent unintended pregnancies in HIV infected women which will help reduce 
the number of babies born with the disease. In this case, VCT and family planning services need to 
include a system for support of such women and counseling that can help them make informed 
decisions concerning childbearing. The third prong is targeted at women who are already HIV positive 
and are either pregnant or breastfeeding. This approach is aimed at preventing the disease being passed 
on to the unborn child or the breastfeeding infant. This can be achieved through access to antiretroviral 
treatment both for the infected mother and the infant. A fourth strategy involves the provision of 
treatment, care and support for HIV positive women, their infants and their family as a whole. This 
strategy aim at better integration of treatment, care, family and community support. 
 
The success of the UN strategies in reducing MTCT varies from country to country due to 
commitment and even within the same country due to coverage and access to ARVs, however, there 
have been reports of comprehensive programs that helped reduce MTCT in many resource limited 
settings (WHO 2010c).    
 
2.6 HIV/AIDS treatment in children 
While prevention of MTCT may help reduce the number of children with HIV/AIDS, treatment with 
antiretrovirals is currently the best option for children who are already infected (WHO, 2006a). It is 
estimated that without ART, about one third of children may not live to see their first birthday while 
more than half of them die before their second birthday (Barth et al, 2011; UNICEF, 2010; Becquet et 
al, 2012). In a cohort study that aimed at determining the survival of new born based on the infection 
status of their mother, the infants and the time at which infection occurred, Chopra and collaborators 
studied 883 mothers and their infants. Their cohort composed of 665 HIV positive and 218 HIV 
negative mothers. They found that 28.4% of children who were exposed to HIV died before six weeks 
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while 56.7% died by the twelfth week. These authors also reported that 81.3% of infected infants who 
died were infected by their third week of life stressing the need for strategies to prevent early infection 
and provision of antiretrovirals to eligible infants (Chopra et al, 2010).   Treatment with antiretroviral 
drugs helps slow progression of the disease and has been shown to greatly improve the health of 
HIV/AIDS patients by decreasing morbidity and mortality due to AIDS. In South Africa, a 
collaborative cohort that represented 20% of children in the South African national treatment 
programme was used to assess paediatric ART outcome and their associations (Davies et al., 2009). 
This cohort involved 7 public sector paediatric programmes in three provinces (Gauteng, Western 
Cape and Kwazulu Natal) and included 6,078 ART-naïve children who were ≤16 years old and who 
started treatment with ≥3 ARV before March 2008. The study which used time to death or loss to 
follow-up, immune status and virological suppression as outcome measures was able to demonstrate 
dramatic clinical benefits for children accessing the national ART programme. These authors reported 
that 82.4% of children experienced virological suppression at 3 years of follow-up while only 16.9% 
and 6.4% were severely immunosupressed at 1 and 3 years respectively. Mortality rate for the cohort 
was 7.7% and an impressive 81.1% of the children were alive and still in care at 3 years.  There was 
however, a high mortality rate among infants and children with advanced disease, thereby stressing the 
need for early diagnosis and treatment. Despite the positive impact of ART on children in this study, 
the authors acknowledged some limitations which included the non-inclusion of high burden 
provinces, the disproportionate representation of sites with tertiary care facilities and the changing of 
the WHO staging system which limits its value as a measure of disease progression (Davis et al, 2009) 
 
In Zambia, an open cohort assessment that used routinely collected data on clinical and immunological 
responses from the medical record system in 18 government primary health facilities in Lusaka 
showed good clinical and immunological outcome of children on ART (Bolton-Moore et al, 2007). 
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The study was aimed at determining secular trends in the characteristic and treatment outcomes of 
children on ART in both rural and urban clinics in Zambia and outcome results were reported for each 
year. In this study, since the authors relied on data abstracted from patient medical records, there is the 
likelihood that some relevant information may not be present and available data may not be complete. 
This fact is acknowledged by the authors for data on anthropometric and laboratory measures (Bolton-
Moore et al, 2007). In addition, it is possible that as the years go by, there are improvements in the  
running of such programmes and methods of data collection which may be reflected in results obtained 
for later years of the programme. Despite these concerns about the study, it is evident that ART 
initiation at an early stage for children can greatly improve outcome of the disease. Analysis of data 
from 1561 children receiving ART who fitted their inclusion criteria, showed that the median CD4 cell 
percentage increased from 12.9% at ART initiation to 27.0% and 28.4% after one and two years of 
ART respectively. 
 
A retrospective cohort study that involved HIV positive children that were followed up for four years 
in two HIV-programmes in Cambodia also showed impressive outcomes but with high mortality and 
loss to follow-up rates before and during the early periods of ART (Raguenaud et al, 2009). This study 
had a sample size of 1168 HIV positive children and sought to measure mortality in both pre-ART 
children and children already on ART. A high mortality and loss to follow-up rate (14.5% and 5.5% 
respectively) was experienced in pre-ART children compared to those on ART (22% and 2% 
respectively). The authors suggest that improvement in such programme outcome may be achieved by 
more timely initiation of ART (Raguenaud et al, 2009). Although this study draws strength from its 
large sample size and the fact that data came from a programme setting, it also had some limitations. 
The causes of death were not reliably ascertained, however, the authors note that since both 
programmes were situated close to a provincial hospital and that doctors performed all consultations, 
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the level of errors in this respect was limited. Another limitation to this study was the loss to follow-up 
rate in the pre-ART patient group which may have led to unreported deaths and consequently an 
underestimation of the mortality rate ratio between the two study groups (Raguenaud et al, 2009). 
 
Another study that looked at 4-year outcome from the pediatric outpatient service at the Chris Hani 
Baragwanath Hospital showed that majority of children in the study achieved viral suppression but 
also high mortality rate (14.5% [95% CI 11.59-18.51]during the first three months and 3.2% [95% CI: 
1.8—3.0] after three months of ART (Meyers et al, 2011). The children also experience a doubling of 
mean CD4 percentage within 12 months of ART initiation increasing from 12.7% to 25.1% with a 
slower rise to 27.9% and 30.6% at 24 and 36months respectively. The high mortality rate during the 
early periods of treatment in most ART programmes may reflect the fact that children are not 
diagnosed early during infection and points to the need for increased awareness of MTCT and better 
and improved methods to detect infection early and start treatment promptly.  
 
Several other studies in Africa and other resource-limited countries have shown clinical, 
immunological and virological outcomes of children on ART similar to those in high income countries 
(Sutcliffe et al, 2008). However, these data are mostly available from urban settings with very few 
studies being dedicated to the analysis of data from ART programmes in rural areas. A study on the 
clinical outcome of HIV-infected children on ART in a decentralized nurse/counselor-led programme 
in KwaZulu-Natal showed that good clinical outcomes can be achieved in rural settings (Janssen et al, 
2009). Using a sample of 477 HIV positive children and survival, mortality and changes in laboratory 
parameters (CD4% and viral load) as outcome measures, the authors were able to show improvements 
in patients on ART.  They showed that the median CD4% increased from 17%  to 22% within 6-12 
months after initiating ART while 73.5% of those whose viral load data were available had a 
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suppression in viral load (<25copies/ml). Mortality was 6.7% while 3.7% were lost to follow-up 
Similar outcome was observed in a retrospective (2-4 years follow-up) cohort of 735 HIV positive 
children in Ndlovu Medical Centre, in rural Limpopo with 63% of children experiencing viral 
suppression within a median of 3 years after initiating ART (Barth et al, 2011).  
 
Despite these impressive outcomes, access to ART especially for children in resource limited settings 
still remains a problem. WHO reported that at the end of 2009 only 38% of HIV-infected children who 
were less than 15 years of age in resource-limited countries needing ART were on therapy (WHO, 
2010b). Indicators used to determine coverage of antiretroviral treatment suggest that adults have 
greater access to ART than children. However, a substantial improvement in access to ART for 
children has occurred over the past years (Unicef, 2010) with the biggest increase seen in low- and 
middle- income countries where approximately 456,000 HIV-infected children were on ART by 
December 2010, an increase from 275,400 in 2008 and 71,500 in 2005 (UNAIDS, 2011; Barth et al, 
2011). 
 
South Africa, which has the largest pediatric antiretroviral programme in the world, has also seen an 
increase in access to ART over the years with more than 36% of HIV-infected children accessing 
treatment by mid 2008 up from 9.4% in mid 2005 and 2.1% between 2002 and 2003. Despite this 
improvement, ART programmes have not been able to reach more than half of the children needing 
treatment based on the national guideline (Davies, 2009). Few data are available that demonstrate the 
success of ART programmes particularly on the virologic outcome of treatment which is very 
important in predicting drug resistance and long-term sustainability of ART programmes (Moultrie et 
al, 2009). In most areas where there is lack of proper laboratory information on virological outcome, 
clinical or immunological decline are usually used to predict treatment failure. However, these 
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measures and virological failure have shown limited correlation as reported by some studies (Barth et 
al, 2010). 
 
The main goal of antiretroviral treatment is to attain a suppression of viral replication and restore 
immune function (Paintsil, 2010). Viral load, CD4 counts (or percentage) in addition to clinical 
outcomes, which are usually manifested by changes in weight and presence or absence of 
opportunistic infections are the outcome measures that are usually used to assess ART programmes. 
Monitoring ART in both resource-rich and resource-poor settings is essential in identifying cases of 
treatment failure which may provide a guide for alternative treatment and also to determine the extent 
to which ART programmes can be strengthened. Comparing data across different settings can help 
identify programmes with greater need.  
 
The World Health Organization (WHO, 2010a) has published a technical report which provides 
guidelines for care of infants and children on ART to help guide health care workers who are involved 
in pediatric ART delivery in resource-limited settings. This list provides the minimum standards of 
HIV care and the type of information to be collected at each clinic visit. Collation and analysis of the 
data collected over a long period of time will be useful in evaluation of local and national programmes 
and standardization of the process of data collection will aid in identifying the strengths and 
weaknesses of ART programmes (WHO, 2010a).   
2.7  Rational  
ART has been shown to provide significant benefits to children accessing them and some rural settings 
have reported excellent outcomes (Barthe et al, 2011; Janssen et al, 2009). 
This study was aimed at describing the long term (at least one year) virologic, immunologic and other 
outcomes of HIV positive children in the Bela-Bela treatment programme. This study was part of a 
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research carried out by the Microbiology and Statistics Departments of the University of Venda that 
was aimed at determining the overall outcome of the HAPG in Bela-Bela. Information on treatment 
outcome may help in assessing progress and effectiveness and therefore identify ways to optimize 
overall performance of the antiretroviral therapy programme. It may also be used to predict long-term 
programme sustainability. 
2.8 Aim of study 
The aim of this study was to describe the long term (> 1year) treatment outcomes of HIV-1 infected 
children in the HIV/AIDS Prevention Group (HAPG) programme in Bela-Bela in the Limpopo 
province of South Africa. 
2.9 Objectives 
1. To describe the virological response of HIV-infected children to antiretroviral treatment (ART)  
2. To describe the immunological response of HIV-infected children to ART.  
3. To describe the clinical outcome of children on ART  
4. To describe loss to follow-up of HIV-infected children. 
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CHAPTER 3: METHODOLOGY 
 
3.1 Study method and design. 
A quantitative approach was used for this study employing a retrospective cohort design. In this type 
of study design, available information on previous exposure is obtained for a defined population and 
then the outcome determined for this population. This type of study takes a look backward and 
examines exposures to suspected risk or protection factors in relation to an outcome of interest. The 
researcher starts the study at the designated time zero and then follows up subjects for the study period 
which has already taken place (Euser et al, 2009). 
 
In this study, the records of a group of children (a cohort) who were HIV positive and who have been 
exposed to antiretroviral treatment were examined. Routine data on CD4 level, viral load, weight and 
other measures that were collected at baseline and every three months after initiation of antiretroviral 
treatment were obtained and analyzed to determine the outcome of the programme on pediatric HIV.  
 
3.2 The setting 
Bela-Bela is a peri-urban town in the Limpopo Province situated 100 km north of Pretoria. It has a 
population of approximately 63,000 people and an unemployment rate of 21% (De Koker et al, 2010; 
Ndjeka and Manhaeve, 2006). In 1996, community members in Bela-Bela who were concerned about 
HIV/AIDS formed the HIV/AIDS Prevention Group (HAPG). This group provides voluntary 
counseling and testing (VCT), and care and support to HIV/AIDS patients. Their activities range from 
prevention campaigns to free VCT and ART. They also provide home-based care and care for 
orphaned children, particularly HIV/AIDS orphans. This group was selected as one of the sites in 
South Africa for the roll-out of ART with funding from the United States President’s Emergency Plan 
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For AIDS Relief (PEPFAR) (Ndjeka and Manhaeve, 2006). Patients who are referred to the HAPG by 
the local clinic and private doctors are included for treatment based on the following criteria: CD4 
count of <200/mm3 and/or WHO stage IV HIV disease. 
3.3 Study population and sample size 
All antiretroviral treatment naïve children under the age of 15 that were enrolled in the HATG 
treatment program in Bela-Bela and started ART between February 2004 and December 2009 were 
included in this study. The ages of the children were obtained from their birth certificates during 
admission/registration to the program. In very rare cases where a birth certificate was not available, a 
road-to-health card was used to ascertain the date of birth. Children who came in from different clinics 
or from neighbouring countries (e.g Zimbabwe) had to provide proof of HIV testing. In cases where 
such proof was not available, another HIV test was conducted and the result kept in the file of the 
patient.  ART was initiated in these children following the guidelines of the South African Department 
of Health. 
 
A total of 71 children were enrolled during this period. A record of all HIV positive children enrolled 
within this period was obtained from the clinic. Sampling a smaller number may not produce results 
that reflect the true outcome of the programme (a particular outcome may be due to chance). A higher 
number of samples could have been better, however, this was not possible since only this number of 
children were enrolled in the program within the study period.  
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3.4 Data collection  
A quantitative method was employed for data collection since the study involved quantification of 
relationships between variables. A list of all the children in the program and their files (which included 
follow-up sheets) were obtained electronically from the clinic. Information from structured patient 
files, and follow up sheets that were routinely recorded were entered into a specific HIV-database. 
These data included information on age, sex, weight, CD4 counts and viral load (Appendix 1) obtained 
on the day of enrolment and subsequently, every three months after treatment has been initiated. For 
the weight, a medical electrical digital scale was used for weighing the children. CD4 counts and viral 
load determination were done by TOGA laboratory in Kempton Park, Johannesburg. Blood samples 
were sent weekly to the lab for CD4 counts and viral load and results sent by Email or extracted from 
the laboratory’s website using specific codes. Information on the type of regimen and other infections 
associated with AIDS were also extracted from the patient file (Appendix 1).  
3.5 Reliability and validity 
Validity refers to the degree to which the results of a study are likely to be true and free of bias. Due to 
the retrospective nature of this study measurement bias could not be overcome since it relied on 
already existing information. All children in the study period were included in the study reducing 
selection bias for this population, however generalizability could be affected depending on how the 
study population compares to other potential target populations. .  
 
Bias and confounding due to data analysis on the other hand can be reduced in order to achieve a high 
level of validity. Since the nutritional status of the children could not be ascertained and younger 
children can loose weight more rapidly in the face of disease than older ones, children were grouped 
according to their age (≤18 months and >18months) and compared for each treatment outcome. 
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There could be unmeasured confounding that could potentially affect the result of this study.  These 
included; inaccurate reporting of age (date of birth) in cases where a birth certificate or a road to health 
card is not available to confirm it and also inaccurate recording of information, as well as other socio-
demographic factors not generally found in the medical record. 
The reliability of a study refers to the reproducibility of the measures of such study if they were to be 
re-tested. The reliability of this study was ascertained based on the number of samples that were 
analyzed. The sample size provided for a 95% confidence interval of ±10% for descriptive estimates. 
3.6 Data analysis 
Outcome measures for this study were virological suppression, CD4 counts, weight and loss to follow-
up. Loss to follow-up was defined as a patient who missed two consecutive clinic visits. Those who 
were lost due to death or moved to the adult group were not considered LTFU. 
All information entered into the clinic electronic record at the time of child visit to ARV clinic by 
clinic staff was obtained from the clinic. This data was then exported on an Excel spreadsheet. The 
data was cleaned and imported into the statistical programme, SAS for statistical analysis. Basic 
frequencies were used to determine trends in categorical data while means and medians were used for 
continuous data. A comparison of CD4 count and viral load by age and gender was assessed. 
Immunological and virological outcomes were assessed by respectively determining the median CD4+ 
T-cell and viral load within the study period. Clinical outcomes were assessed by determining the 
proportion of children who were underweight within the period of study. 
 
Three models were fitted with CD4+, viral load and weight as response variables. A fixed effect linear 
mixed model was used to analyze the data. The linear mixed model allows a flexible approach to 
modeling longitudinal data. The linear mixed model handles unbalanced data with unequally spaced 
time points and subjects observed at different time points. Using all the available data the analysis 
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directly models the covariance structure and provides valid standard errors and efficient statistical 
tests. CD4+ cell count and viral load were transformed using natural log to make sure the distribution 
was close to normal distribution. All analyses were conducted using SAS version 9.3 (SAS Inc., Cary, 
North Carolina). The variables were defined as significant at 5% level of significance. 
 
Survival time (time from first treatment to death) was evaluated by Kaplan-Meier survival analysis 
and multivariate Cox proportional hazards modeling. Variables that were significantly associated with 
death in univariate analysis at the p= 0.2 level were chosen for inclusion for evaluation in multivariate 
modeling. Only those variables that retained significance (p<0.05) in the multivariate model were 
further included in the final model. Potential independent predictor variables were evaluated for 
colinearity by examining non-parametric rank correlation coefficients and a variety of models were 
tested and compared using the -2log likelihood measures for goodness of fit.  
For children who were lost to follow-up, data were censored as of the last date of clinic visit and they 
were not considered to have died.  
3.7 Ethical considerations 
A letter of permission allowing the Department of Microbiology of the University of Venda to use 
data from the treatment was obtained from the HAPG board (Appendix 2). The names of the patients 
whose information were used were kept confidential. Once extracted to Excel, names were deleted and 
only record numbers were used. Individual data were presented only as aggregate results. No known 
risk to the patient was associated with this study and no patient benefitted personally from the 
research. However, results from the study may help in the design of HIV treatment programmes in 
future. The findings of this research will be shared with the HAPG board.  The study was approved by 
the UWC Higher Degrees and Research Ethics committees. 
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CHAPTER 4: RESULTS 
 
4.1 Characteristics of Subjects at ART initiation 
A total of 71 children were included in this study. The median age for the study participants was 5 
years (interquartile range, 2-7) with 8.8% (6/71) of them being 18 months or less. Thirty five children 
(49.3%) were females. The median CD4+ T cell count at ART initiation was 358 cells/mm3 (IQR 
203.25-570.75cells/mm3) while the median viral load was 125673 (IQR 58094-328424.5 viruses/µL). 
The median weight at ART initiation was 14.5kg (IQR 11.0-18.35) (Table 1).  
4.2 ARV Treatment 
In all cases, children started triple combination drugs of stavudine (d4T), lamivudine (3TC) with either 
effavirenz (71.8%). lopinavir/ritonavir (14.1%) or Nevirapine (5.6%). Two (2.8%) patients started 
with Lamivudine-zidovudine-effavirenz combination while a single patient had zidovudine-
lamivudine-nevirapine combination regimen. At ART initiation, 74.6 % of children had viral load 
greater than 50,000virus/µL while 23.94% had CD4 counts <200. During the study period, 19.7% 
(14/71) of patients changed regimen, 85.7% of them were introduced to AZT while 14.3% included 
didanosine (ddl) in their combination. A single patient was changed to second line drugs. 
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Total 
 
 
2004 2005 2006 2007 2008 2009 
 
Number of children 
enrolled 71 7 20 21 9 12 2 
 
 
Female, n (%) 35(49.3) 3(42.9) 7(35) 12(57.1) 7(77.8) 6(50) 0(0) 
 
 
Age, Median (IQR) 5(2-7) 7(6-7) 5(1.25-1.75) 5(4-7) 3(1-6) 4(3.5-7.5) 6 
≤18months, n (%) 6(8.8) 0(0) 1(16.7) 1(16.7) 3(50) 1(16.7) 0(0) 
 
 
CD4 counts, Median (IQR) 358(203.25-) 207(83-522) 238(144-450.5) 509(356-652) 266(220-452) 391(284-584.5) 
319.5(261.25-
377.75) 
 
 
Weight Median (IQR) 14.5(11-18.35) 16.5(15.7-18.625) 15.3(9.5-17.85) 13.7(11.375-18.475) 13.4(7.5-17) 12.9(11.6-15.625) 19.7(18.75-20.65) 
 
 
WAZ Z score 
-2.56(-4.12- 
 -1.6675) -3.26(-5.315 -2.25) 
-2.125(-3.645-  
-1.695) 
-2.63(-3.91-  
-1.08) 
-3.6(-4.06- 
-2.9) 
-2.66(-4.3425- 
-1.65 
-0.395(-1.0775- 
0.2875) 
 
WAZ <-3 n(%) 26(36.62) 4(57.14) 5(25.00) 6(28.57) 6(66.67) 5(41.67) 0 
Viral Load Median(IQR) 
 
125673(58094-
328424.5) 
124860(108278-
261377) 
117703.5(35162-
500000) 
144272(13666-
248162) 
129048(121179-
278948 
90477(58643.5-
282664) 
177466(177466.5-
17747.5) 
 
Regimen n(%)        
d4T-3TC-EFV 51(71.8) 5(9.8) 13(25.5) 17(33.3) 5(9.8) 9(17.6) 2(3.9) 
AZT-3TC-EFV 2(2.8) 2(100.0)      
d4T-3TC-NVP 4(5.6)  3(75.0)) 1(25.0)    
d4T-3TC-LPV/r 10(14.1)  3(30.0) 1(10.0) 4(40.0) 2(20.0)  
AZT-3TC-NVP 1(1.4)   1(100.0)    
d4T-3TC-Kal 1(1.4)   1(100.0)    
Missing info 2(2.8)  1(50.0)   1(50.0)  
 
 
 
Table 1: Characteristics of children starting ART 
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Table 2: Immunological, clinical and virological outcome of children on ART 
 
 ART 
initiation 
(n=71) 
6wks 
(n=43) 
3months 
(n=48) 
6months 
(n=43) 
12months 
(n=34) 
18months 
(n=28) 
24months 
(n=24) 
30months 
(n=16) 
36months 
(n=6) 
42 months 
(n=2)  
48 
months 
(n=1) 
CD4 
Median 
(IQR) 
358(203.25- 
570.75) 
 
639(337.5
-1218) 
 
750(462.25-
1150.25) 
 
863(432.5-
1219) 
 
856(483.5-
1114.75) 
 
905(571-
1149) 
 
1039.5(639.
25-1166.25) 
 
950(645.5
-1097.25) 
 
769.5(633
-1131.75) 
 
1323(1212.
5-1433.5) 
 
 
Weight 
Median 
(IQR) 
14.5(11-
18.35) 
16.3(12-
18.95) 
 
17.3(12.88-
20.15) 
 
18.0(13.48
-21.08) 
 
18.85(14.53
-21.13) 
 
20.25(17.
2-23.8) 
 
21.45(16.15
-23.73) 
 
23.7(21.4
5-25.85) 
 
25.1(23.5-
34.13) 
 
31.5(28.1-
34.9) 
 
 
WAZ 
Median 
(IQR 
-2.56 
(-4.12-  
-1.6675 
 
-2.34 
(-3.41- 
-1.24) 
 
 
-1.89 
(-2.535- 
-1.045) 
 
-2.015 
(-2.9225- 
-0.9925) 
 
-2.09 
(-2.72- 
-1.115) 
 
-2.115 
(-2.66- 
-1.2025) 
 
-1.705 
(-2.925- 
-1.16) 
 
-1.79 
(-2.665- 
-1.485) 
 
-1.745 
(-2.3925- 
-1.4725) 
 
-0.695 
(-0.9725- 
-0.4175) 
 
-2.02 
 
WAZ 
<-3 
n(%) 
26(36.62) 15(34.88) 
 
8(16.67) 
 
10(23.25) 
 
10(29.41) 
 
5(17.86) 
 
5(20.83) 
 
2(12.5) 
 
0(0) 
 
0(0) 
 
0(0) 
 
VL <50 
n(%) 
0 (0) 29(67.44) 30(62.50) 32(74.42) 24(70.59) 23(82.14) 19(79.17) 11(68.75) 5(83.33) 2(100) 1(100) 
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4.3 Immunological Outcome 
The median CD4+ count increased from 358 cells/mm3 (IQR 203.25-570.75) at ART initiation to 
863 cells/mm3 (IQR 432.5-1219) after six months of ART initiation then stayed more or less 
constant up to 30 months of follow-up (Table 2). On average, the CD4+ count increased over time 
(figure 1). The statistical analysis result shows that the covariate “Time” is a significant predictor 
of CD4+ values (p <0.0001). Time has a significant positive effect i.e. as time goes on, the CD4+ 
count increases. However, a significant (p<0.0001) negative relationship was observed between 
age and CD4 count when children ≤18 months and those >18 months were analyzed (Table 3). 
There was no difference in the trend of CD4 counts between male and female patients (p=0.6621). 
 
Table 3: Solution for Fixed Effects – CD4 
Effect SEX Estimate Standard Error DF t Value Pr > |t| 
Intercept  10.4981 1.2580 74.5 8.34 <.0001 
month  0.7389 0.1113 306 6.64 <.0001 
AGE  -0.8079 0.1296 95.2 -6.23 <.0001 
SEX Female 0.5260 1.1970 52.6 0.44 0.6621 
SEX Male 0 . . . . 
month*month  -0.03369 0.007284 303 -4.63 <.0001 
month*month*month  0.000484 0.000125 302 3.88 0.0001 
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Figure 1: Individual profile of CD4 counts (cells/mm3) for children on ART showing the average 
trend (red line). 
 
4.4 Virological Outcome 
Among the 71 children who started ART 59 (83.1%) had at least one follow-up viral load 
measurement. Among those who did not have any follow-up viral load measurement, 50% (6/12) 
died before their next (the six weeks) appointment. The median viral load at ART initiation was 
125673 RNA copies/ml (IQR 58094-328424.5). After six weeks of starting ART, 67.44% of 
children experience viral suppression (<50 RNA copies/ml) and this proportion increased to 
70.59% and 79.17% after one and two years respectively (Table 2). 
The mean profile plot for viral load shows that viral load decreases as time increases (Figure 2). 
This is supported by the statistical analysis which shows a negative time effect (p <0.0001). As 
time increases the viral load decreases. There is also a significant age effect (p <0.0010) with viral 
load decreasing as age increases (Table 4). Like CD4 counts, there was no significant gender 
difference in the viral load trend (p=0.7516). 
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Table 4: Solution for Fixed Effects – Viral load 
Effect  Estimate Standard Error DF t Value Pr > |t| 
Intercept  21.2840 2.0902 64.8 10.18 <.0001 
month  -3.2504 0.3706 330 -8.77 <.0001 
AGE  -0.7395 0.2137 53.9 -3.46 0.0011 
SEX Female -0.5623 1.7651 42.2 -0.32 0.7516 
SEX Male 0 . . . . 
month*month  0.1718 0.02434 324 7.06 <.0001 
month*month*month  -0.00248 0.000417 325 -5.94 <.0001 
 
 
 
Figure 2: Individual viral load (RNA copies/ml) profile for children on ARTs showing average 
trend (in red)  
 
 
4.5 Clinical Outcome 
The mean profile plot for WAZ score shows that weight-for-age for children on ART increased 
within the first three months and remained steady over a period of two years before showing an 
increase (figure 3). The median weight of children at ART initiation was 14.5Kg (IQR 11.0-18.35) 
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increasing to 18Kg (IQR 13.48-21.08) after six months of treatment and 18.85 (IQR 14.53-21.13) 
after one year of follow-up (Table 2).  The median weight-for-age within this period was -2.56 
(IQR -4.12 - -1.6675), -2.015 (IQR -2.9225 - -0.9925) and -2.09 (IQR -2.7 - -1.115) respectively. 
The statistical result shows that the covariates “Time” and “Age” are significant predictors of 
weight (p <0.0001 and p<0.0001 respectively). Time has a significant positive effect i.e. as time 
goes on, the weight also increases.  
 
 
Figure 3: Individual weight profile of children on ARTs at initiation time and follow-up period 
showing average trend 
 
4.6 Transfers, mortality and loss to follow-up 
Within the study period, three children (4.23%) grew out of the children group and were transferred to 
adult group while some patients (7.04%) moved from Bela-Bela to another town or even province. 
Nineteen percent (14/71) of patients died during the study period and 21.43% of these were children 
who were 18 months or less (Table 5). Mortality was the same for male and female with all patients 
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dying within the first year of ART initiation. Ninety two percent of those who died had viral loads 
>50,000 while 72.4% had CD4 counts less than 350 cells/mm3 at the time they commenced ART. 
Five children (7.04%) were lost to follow-up and their files closed due to non-adherence. All five 
patients were lost to follow-up within two years of ART initiation with only one of them receiving 
treatment for up to two years. After experiencing virological suppression, children were referred to 
PHC where they continued treatment. Most of the children were transferred to PHC at the end of 2009 
and as shown on table 3 by the end of 2009, 33 children (46.5% of the 71 who started ART at the 
clinic) moved to PHC, 25 (75.8%) of them are still receiving treatment as at August 2012. Two 
children died at PHC while 4 have been lost to follow-up (Table 5). 10 (14.08%) children are still 
receiving treatment at the HAPG clinic.  
 
Table 5: Summary of cohort of children who initiated treatment at the HAPG clinic in Bela-Bela after 
four years of follow-up 
 
Number starting ART at clinic n (%) 71 
Still on ART at clinic 
 
Died on ART at clinic 
 
LTFU (non adherence) 
 
 
Transferred (other town or province) 
 
To adult group 
 
referred to PHC(still on treatment) 
 
referred to PHC died on ART 
 
referred to PHC LTFU 
 
referred to PHC transferred 
 
10(14.08) 
 
14(19.72) 
 
5(7.04) 
 
 
5(7.04) 
 
3(4.23) 
 
25(35.21) 
 
2(2.82) 
 
4(5.63) 
 
2(2.82) 
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4.7 Survival Analysis 
Not including the 14 children who died, 57 observations were censored. In Kaplan-Meier analysis 
CD4 count at ART initiation was a significant univariate predictor of death (p=0.0206), and age less 
than 18 months (p=0.1235) was a univariate predictor by Cox proportional hazards modeling 
(CPHM) (Table 4a). Kaplan-Meier (K-M) survivor curve for CD4 count at time of initiating ART 
(Figure 4) shows that there is a difference in survival between those with higher CD4 
(>358cells/mm3) and those with lower CD4+ count (<358 cells/mm3). The higher K-M curve for 
those with higher CD4+ group suggests that this group has a higher chance of long term survival. A 
log-rank test statistic value of 5.4 confirms this difference with an approximate p-value of 0.0206. 
The multivariate CPHM shows that age and baseline CD4+ are significant predictors of survival 
duration (Table 4a).  
 
Table 6a: Analysis of Maximum Likelihood Estimates (full model) 
Parameter  DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Label 
AGE  1 -0.27362 0.12043 5.1622 0.0231 0.761  
vl_cat 0 1 -0.57593 0.77391 0.5538 0.4568 0.562 Rank for Variable VL 0 
SEX Female 1 0.57314 0.76066 0.5677 0.4512 1.774 SEX Female 
cd4_cat 0 1 2.27552 0.93589 5.9117 0.0150 9.733 Rank for Variable CD4 0 
 
 
Table 6b: Analysis of Maximum Likelihood Estimates (reduced model) 
Parameter  DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard 
Ratio 
Label 
AGE  1 -0.28217 0.11061 6.5072 0.0107 0.754  
cd4_cat 0 1 2.27124 0.86414 6.9081 0.0086 9.691 Rank for Variable 
CD4 0 
 
Here it is confirmed again that there is a significant difference between the two baseline CD4+ 
groups (0=CD4+ <358, 1=CD4+>358cells/mm3). The estimated coefficient for CD4 group is 2.3 
with p-value 0.0086 (Table 6b). Hence, with other covariates fixed, baseline CD4+ group 0 have an 
increased hazard, and, hence, have shorter expected survival time than those in Group 1. Fixing 
other covariates, the hazard ratio between Group 0 and Group 1 is 9.7. This means that, with other 
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covariates fixed, patients with Initial CD4+ group 0 are 9.7 times more likely than baseline CD4+ 
group 1 to have shorter survival. The estimated coefficient for age is -0.2822 with p -value 0.0107 
(Table 6b). Hence, fixing other covariates, older children have a decreased hazard, and, hence, have 
longer expected survival time than younger children. 
  
Figure 4: Probability of patient survival as predicted by CD4 count at ART initiation. 0 = CD4 count 
<361 cells/mm3, 1 = CD4 count > 361 cells/mm3 children less than 18months, 1 = children > 18 
months 
 
Viral load (p=0.4568) and sex (p=0.4512) were not significant predictors of death (Table 6a). There 
was no significant difference in survival between male and female patients.  
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CHAPTER 5: DISCUSSION AND CONCLUSION 
5.1 Discussion 
HIV in children initially did not attract as much attention as it did with adults but in recent years, 
paediatric HIV has become an increased priority due to its devastating effects on children and young 
adults. In South Africa, a significant number of children die from HIV and more are being infected and 
still live with the disease. In the words of the South African Department of Health report, “children 
usually do not have sufficient access to AIDS treatment and care because available services are mostly 
designed for adults” (DoH, 2009).  
 
With South Africa having the largest ART program in the world and at the same time seeking ways to 
increase and improve access for the large number of HIV/AIDS patients in the country, it is essential 
that key outcomes be understood that will help in planning for the changing needs of patients, planners 
and provider services. In most industrialized countries, HIV treatment is individualized while in low- 
and middle-income countries, ART programmes follow WHO developed recommendations due to 
lack of or limited resources in the health systems in these countries. These ART programs have been 
shown to be as effective as those of the individualized programs (Sutcliffe et al, 2008; Keiser et al, 
2008). 
 
This study looked at the outcome of the ART program of a peri-urban town in the Limpopo Province 
of South Africa. It described the characteristics of children in this program at ART initiation and the 
long term outcome of the treatment program. Parameters that have been used to assess the outcome of 
treatment programs include CD4 counts (immunological), viral load (virological), weight (clinical), 
mortality and loss to follow-up. After an initial six weeks and three months monitoring of patients, a 
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six monthly virological, immunological and clinical monitoring was performed for each child in the 
cohort. Based on these parameters, the findings of this study demonstrate good outcomes for children 
receiving treatment at the HAPG clinic and suggest that positive outcomes are possible in low and 
middle- income settings.  
 
As shown in Table 2, the median CD4 level was more than double the baseline level after six months 
of follow up. This is in line with many similar studies that have shown positive outcomes for children 
on ART (Davis et al, 2009; Cohen et al, 2009; Bolton-Moore et al, 2007). CD4 is the most common 
measurement of disease severity and staging in HIV positive patients particularly in the absence of 
viral RNA testing. Even in the presence of viral load testing, CD4 counts and percentage is important 
in determining how well a patient can be able to fight other infections. With children predisposed to 
other bacterial and fungal infections in the face of HIV, an improvement in their CD4 counts would 
mean improved ability to fight opportunistic infections.  
 
A similar trend as CD4 was observed for weight with the median weight for age z scores of children in 
this cohort showing an improvement within two years of follow up (Table 2). Improvement in weights 
and appropriate growth in a child is an indication that malnutrition decreased during treatment. 
Although there were some cases of children who were underweight for their age (z score <-3) within 
the study period, overall, children’s growth was within acceptable range as measured by WAZ. The 
nutritional status of HIV infected children has been shown to correlate with their immunological and 
virological status with a negative correlation observed between viral load and certain nutritional 
indicators (Steenkamp et al, 2009). Poor nutrition compromises the immune function of children 
thereby predisposing them to infections. In this cohort, good clinical outcome was matched by 
improved immunological and virological outcomes (Table 2).   
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A decline in viral load was observed during the period of this study (Table 2, Fig 2). Virological 
suppression was observed in more than 70% of children after one year on treatment. This outcome is 
comparable to similar smaller and larger studies that have been carried out in Sub-Saharan Africa 
(Sutcliffe et al, 2008). The availability of viral load testing was of great advantage in this cohort since 
virological data could be compared with immunological information to aid in treatment decision. In 
many low and middle income settings, viral RNA determination is rare and as such, treatment is based 
mainly on CD4 level alone making it difficult to be able to determine treatment failure, viral rebound 
and when to switch to other treatment options. Change in treatment for children in the HAPG clinic 
was based on both viral load and CD4 information.  
 
The aim of antiretroviral treatment is to reduce viral load to levels that may not cause illness and 
cannot be transmitted. Like with adult patients, children require a combination of at least three drugs 
in order to achieve viral suppression. The recommended combinations usually include two nucleoside 
reverse transcriptase inhibitors (NRTI) and either one non-nucleoside reverse transcriptase inhibitor 
(NNRTI) or a protease inhibitor. For infants, NVP and two NRTI is recommended for those who were 
never exposed to ART and for infants whose exposures cannot be determined. Lopinavir/ritonavir 
replaces NVP for children exposed to NVP or other NNRTI (WHO, 2010b). In this study Lamivudine 
(100%) and Stavudine (92.9%) were the most common NRTI backbone used. This is in line with the 
WHO recommendation for infants and children. Ten patients had the LPV/r combination pointing to 
the fact that ten children were exposed to ART either through the mother or as an infant during the 
early days of live. Although LPV/r has been demonstrated to cause viral suppression in children, it is 
however cautioned that its palatability and possible interactions be taken into consideration before 
using LPV/r based drugs for first line therapy (Meyer et al, 2012).  
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Stavudine was one of the NRTI used in 92.9% of patients in this study. This drug has been associated 
with toxicity resulting in its substitution in some patients. In this study, Stavudine was replaced with 
Zidovudine in patients who experienced lactic acidosis (either mild moderate or severe) and those with 
hyperlactataemia. Treatment failure was also observed in some patients and either Didanosine (ddl) or 
Zidovudine was a replacement of choice. Despite its known toxicity which in some cases may result in 
its replacement in some treatment combinations, Stavudine is still a safe and effective option for 
children in situations where treatment options are limited (Palmer et al, 2012). 
 
Some adult studies have shown gender associations in HIV treatment outcomes (Cornell et al, 2012; 
Collazos et al, 2007; Chen et al, 2008) while others did not (Nicastri et al, 2007). In this study, 
however, there was no significant difference in the trends observed for viral load (p=0.7516), CD4 
counts (p=0.6621) and weight between male and female patients. 
 
Loss to follow-up during the study period was 7.04% which compares with some earlier studies that 
were done in some Sub-Saharan countries (Sutcliffe et al, 2008). It has been observed that loss to 
follow-up in paediatric ART has not increased in recent years with high numbers observed mostly in 
bigger facilities that are burdened with large patient loads (Fatti et al, 2011). In such situations, it is 
difficult to keep track of every single patient given the limited resources, particularly human resources. 
The HAPG clinic is located in a peri-urban town and patients (adults and children) are monitored on a 
regularly basis including home visits by members of the group and community workers.   
 
By the end of 2009, more than 65% of children were still on treatment and only a single patient 
switched to second line regimen (usually an indication of treatment failure probably due to virus 
resistance to initial drugs). Although AZT was introduced in some patients, the fact that only a single 
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patient switched to second line treatment points to the ability of patients to adhere to their treatment 
and therefore minimize the selection of resistant viruses. Development of resistance has been 
associated with the lack of proper viral load monitoring, drug interaction, poor adherence and/or drug 
interruption due to non-availability of drugs and the use of substandard dose of antiretroviral drugs 
which may lead to virus selection of resistant mutations (Hamers et al, 2012). Change of regimen for 
children in this cohort was due to development of conditions such as mild or moderate lactic acidosis 
(35.7%), hyperlactaemia (28.5%) and treatment failure which could be associated with resistance 
(35.7%).  On the other hand, the low number of children switching treatment may point to the fact that 
care providers may be concentrating more on adherence counseling and failing to see the need for 
treatment change in the face of virological failure. 
 
Early mortality in treatment has been reported in many ARTs programs particularly for children less 
than 18 months (Meyers et al, 2011; Fatti et al, 2008). In this study, mortality was recorded within the 
first year of treatment initiation with most children (71.43%) dying within 90 days of treatment. This 
was probably due to the advanced disease stage of the patients since most of the patients who died on 
treatment had CD4 <350 cell/µL and viral load >50,000copies of RNA. Similar results have been 
obtained in other cohort studies (Meyer et al, 2012; Barth et al, 20011; Boulle et al, 2008) with direct 
correlation between mortality and low CD4% and low weight for age at the time treatment was 
initiated. The high proportion (42%) of children less the 18 months who died may reflect the fact that 
diagnosis was not prompt and children were not able to access treatment on time. WHO recommends 
ART initiation in infants and young children irrespective of disease stage or CD4 count. However, not 
all settings are well resourced to follow these recommendations and as such, treatment in many cases 
follow the disease stage system. The WHO 2008 recommendation was adopted in South Africa two 
years after it was published thus treatment of children in this cohort did not follow the revised South 
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African guidelines. Treatment was provided to all patients (children and adults) with CD4≤200 cell/µL 
and at stage IV of the disease. Immune reconstitution inflammatory syndrome (IRIS), did not account 
for the high mortality experienced in patients in this cohort. IRIS is an illness that occurs in a small 
proportion of patients soon after ART commencement due to a rapid response of the immune system 
to opportunistic infections, which were initially present in the patient, but were dormant and 
asymptomatic. The symptoms of IRIS are normally mild, but may be life threatening in certain cases, 
with patients starting ART when the immune system is severely damaged being at higher risk of 
developing IRIS (Muller et al, 2010). Four children developed tuberculosis (TB) and were treated. 
None of the TB patients died on ART. Non-tubercular mycobacterium was not seen in any of the 
patients. 
 
5.2 Study Limitations 
Since data was collected retrospectively, all relevant information was not available and some of the 
available data were incomplete. In addition, errors in recording some information and bias due to 
unmeasured determinants cannot be ruled out. 
 
5.3 Conclusion 
The overall findings of this study are similar to other studies that have been conducted in both urban 
and rural settings and points to the need for regular program evaluation to determine the ever changing 
need of HIV infected children in a country that has a high burden of the disease. The study shows 
good outcomes for children in the program but recorded a high mortality occurring within the first 
year of treatment initiation. This suggests the need for early diagnosis and early initiation of treatment 
particularly in children less than 18 months. Although the program recorded a more than 70% patient 
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retention, more efforts need to go into dealing with adherence and in this light, home visits and 
community support need to be strengthened. 
5.4 Recommendations 
With more than 90% of children being infected through MTCT, a programme that will help reduce 
MTCT will be the most effective way to fight paediatric HIV worldwide. While the HAPG 
programme shows good outcome for children, there is still a need for improvement to attain better 
outcomes. The high mortality at early age and within 90 days of ART initiation highlights the need 
for early identification/diagnosis of infected and exposed children and early initiation of treatment. 
This can be achieved by promoting VCT through integration of maternal and child health 
programmes. Since the children in this cohort started treatment before South Africa adopted the 
current WHO guidelines, it is recommended that the programme follows the recent guidelines for 
future children that enroll at the clinic. 
 
LTFU and poor adherence has been observed in many ART programmes in Africa and adherence to 
a greater extent determines the efficacy and durability of ART regimen. In this light, a system of 
adherence counseling and monitoring be put into place to help patients follow their treatment 
accordingly. It will also be beneficial to qualitatively research on non-adherence to determine 
reasons why some patients are unable to follow their treatment and therefore design programme to 
address such. 
 
WHO recommends that each child receives treatment irrespective of CD4 counts and disease stage, 
however, different settings and provinces have different challenges in paediatric ART delivery. In 
this respect, the Government should set out national standards but at the same time research the 
needs of low income settings and work towards addressing such needs. It is also recommended that a 
provincial and regional prevalence be determined in order to access whether the proportion 
accessing treatment reflects the expected proportion that is infected. 
 
There is always the need for human resources in the delivery of ART, both adult and paediatric. A 
programme to train more counselors and community workers is of the essence in the general fight 
against HIV/AIDS. 
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APPENDICES 
 
Appendix 1: Patient information recorded at baseline and at every follow-up 
after initiation of treatment 
 
Patient No 
Date of birth 
Age  
Sex 
Weight 
Height 
WHO stage 
CD4 count 
Viral load 
Treatment (drug type) 
Treatment change? (Yes/No). If yes, New treatment 
Other infections associated with HIV 
Referred? 
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Appendix 2: Letter of permission from the HAPG 
 
 
 
 
 
